University of Barcelona’s Àlvar Agustí discusses what is new in the 2027 GOLD report and why the traditional narrative of ...
Imperial College London’s Jadwiga A. Wedzicha, MD, discusses anti-alarmin trial results in COPD and where biologics may fit ...
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and ...
The Community Oncology Alliance said final 2027 Medicare payment rules address longstanding gaps between hospital and ...
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit ...
More than 4 in 5 patients with hand eczema referred for patch testing at a Shanghai dermatology hospital reacted to at least ...
The EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.
Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.
Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.
Pooled data on 2698 patients tie rituximab maintenance after bendamustine-rituximab to better PFS and OS in mantle cell lymphoma.
In an insured population with advanced lung cancer, clinical trial participants had lower or similar total health care costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results